Inclusion criteria:

          1. histologically confirmed pancreatic cancer, virus-associated tumors [including
             papillomaviruses-related cancers (cervical, head and neck, and nasal), Epstein-Barr
             virus (nasopharyngeal carcinoma) and Kaposi's sarcoma-associated herpes virus),
             non-small cell lung cancer, soft-tissue sarcomas, bladder cancer, triple negative
             breast cancer. For population 4, diagnosis must be confirmed by the RRePS Network as
             recommended by the French NCI,

          2. Metastatic disease,

          3. Age ≥ 18 years,

          4. ECOG ≤ 1,

          5. At least two lesions: one lesion that can be treated by radiotherapy and one site of
             disease that must be uni-dimensionally ≥ 10 mm considered as measurable according to
             RECIST v1.1. This lesion will not be treated by radiotherapy, however, note that
             lesion(s) that will be treated by radiotherapy will also be considered as measurable.
             Note that the largest size of the metastases to be irradiated will be 3cm,

          6. Life expectancy > 6 months,

          7. At least one tumor site that can be biopsied for research purpose. Tumor lesion in
             close proximity to vascular structures such as large vessels, aneurysm or pulmonary
             arteriovenous malformation will not be considered for biopsy,

          8. Availability of archived paraffin-embedded tumor tissue for research purpose,

          9. Participant must have advanced disease and must not be a candidate for other approved
             therapeutic regimen known to provide significant clinical benefit based on
             investigator judgement,

         10. Participants who received prior anti-PD-1/L1 therapy must fulfill the following
             requirements

               -  Have achieved a complete response, partial response or stable disease and
                  subsequently had disease progression while still on anti-PD-1/L1 therapy

               -  Have received at least two doses of an approved anti-PD-1/L1 therapy (by any
                  regulatory authority)

               -  Have demonstrated disease progression as defined by RECIST v1.1 within 18 weeks
                  from the last dose of the anti- PD-1/L1 therapy.

         11. Adequate hematological, renal, metabolic and hepatic functions

         12. No prior or concurrent malignant disease needing an active treatment,

         13. At least three weeks since last chemotherapy, immunotherapy or any other
             pharmacological treatment and/or radiotherapy,

         14. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment,
             excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2,

         15. Women of childbearing potential must have a negative serum pregnancy test within 7
             days prior to inclusion.

         16. Both women and men must agree to use an effective method of contraception throughout
             the treatment period and for five months after discontinuation of treatment.

         17. Voluntary signed and dated written informed consents prior to any specific study
             procedure,

         18. Participants with a social security in compliance with the French law.

        Exclusion criteria:

          1. Previous treatment with a TLR agonist

          2. Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal
             metastases,

          3. Women who are pregnant or breast feeding,

          4. Participation in a study involving a medical or therapeutic intervention in the last
             30 days,

          5. Known hypersensitivity to CHO cell products or to any involved study drug or of its
             formulation components,

          6. History of severe allergic anaphylactic reactions to chimeric, human or humanized
             antibodies, or fusion proteins,

          7. Treatment with systemic immunosuppressive medications including, but not limited to,
             cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents within
             2 weeks prior to inclusion.

          8. Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             before inclusion,

          9. Any of the following cardiac criteria: congestive heart failure ≥ New York Heart
             Association (NYHA) class 2, unstable angina, new-onset angina, myocardial infarction
             less than 6 months before inclusion, uncontrolled cardiac arrhythmias, known left
             ventricular ejection fraction (LVEF) <50%

         10. Individuals deprived of liberty or placed under legal guardianship,

         11. Prior organ transplantation, including allogeneic stem cell transplantation,

         12. Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, cirrhosis, fatty liver and inherited liver disease,

         13. History of intra-abdominal inflammatory process within the last 12 months such as, but
             not limited to, diverticulitis, peptic ulcer disease or colitis.

         14. History of autoimmune disease including, but not limited to systemic lupus
             erythematosus (SLE), Sjögren's syndrome, glomerulonephritis, multiple sclerosis,
             rheumatoid arthritis, vasculitis, systemic immune activation, inflammatory bowel
             disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's
             granulomatosis, Guillain-Barré syndrome, Bell's palsy.

         15. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan.

         16. Poorly controlled Type II diabetes mellitus defined as a screening fasting plasma
             glucose ≥160 mg/dL (or 8.8 mmol/L).

         17. Severe infections within 2 weeks prior to inclusion, including but not limited to
             SARS-Cov-2 infection, hospitalization for complications of infection, bacteremia, or
             severe pneumonia.

         18. Received therapeutic oral or IV antibiotics within 2 weeks prior to inclusion.

         19. Participant has spinal cord compression not definitively treated with surgery and/or
             radiation or previously diagnosed and treated spinal cord compression without evidence
             that disease is clinically stable at least 14 days prior to inclusion.

         20. Administration of a live, attenuated vaccine within 4 weeks before the start of study
             medication .

         21. Has known active hepatitis B or hepatitis C,known history of Human Immunodeficiency or
             known acquired immunodeficiency syndrome, known history of tuberculosis

         22. Patients with current retinal disorder confirmed by retinal examination (external
             ocular examination, routine slit lamp biomicroscopy of anterior ocular structures and
             evaluation of the anterior and posterior chamber,

         23. Patients who wear contact lenses unable to replace them with glasses.